



COUNTY OF SAN LUIS OBISPO HEALTH AGENCY
PUBLIC HEALTH DEPARTMENT
PROVIDER HEALTH ADVISORY

Paxlovid Commercialization: Resources for Pharmacies and Patients

Date: March 1, 2024

Contact: Rick Rosen, MD, MPH, frosen@co.slo.ca.us, 805-781-5500

The FDA has made an [update](#) to the Paxlovid Emergency Use Authorization (EUA) [Letter of Authorization](#) stating that the EUA-labeled Paxlovid distributed by the U.S. government (USG) will remain authorized for use only through March 8, 2024. With this step, Paxlovid is fully transitioning to the commercial market.

The costs of Paxlovid are likely to be prohibitive for many patients who are at high risk for severe COVID-19 illness, including those with commercial insurance. Programs are available to help cover the cost of Paxlovid, thereby helping prevent potentially severe illness, hospitalization and death. Pharmacies and organizations like yours play an important role in informing patients about these programs and encouraging them to enroll if eligible.

The federal government has worked with Pfizer to maintain broad and equitable access for eligible patients upon commercialization. Pfizer is supporting access through the PAXCESS Patient Support Program, with details available at [PAXCESSPatientPortal.com](https://paxcesspatientportal.com) or 1-877-C19-PACK (1-877-219-7225). The PAXCESS Patient Support Program includes two programs:

- **For patients with private (commercial) insurance:** A Pfizer Co-Pay savings program is available at www.paxlovid.com/enroll-in-co-pay-program.
- **For patients with Medicare or Medi-Cal (Medicaid) and those who are uninsured:** A U.S. Government Patient Assistance Program (USG PAP) operated by Pfizer for Medicare, Medicaid, and uninsured patients to receive USG-procured Paxlovid at no charge through 2024. As part of participating in the USG PAP operated by Pfizer, pharmacies will receive reimbursement for the product that has been dispensed, as well as applicable fees. For more information about pharmacy participation in the program, please contact the program vendor at PharmacyNetworkContract102101@assistrx.com or (407) 794-8778, or visit <https://pharmacy.iassist.com>. Eligible patients with a prescription can enroll online at <https://paxlovid.iassist.com> or 1-877-219-7225.

CMS has also provided [guidance](#) on additional mechanisms for some Medicare beneficiaries to access Paxlovid for free without the need to enroll.

To support pharmacies in sharing this information with patients, Public Health staff will be delivering printed flyers to pharmacies in the weeks ahead. A copy of the flyer is attached. If your organization would like copies of this flyer to share with people you serve, please let us know.

Public Health Department

2191 Johnson Avenue | San Luis Obispo, CA 93401 | (P) 805-781-5500 | (F) 805-781-5543

www.slopublichealth.org

If you have questions or would like support in connecting patients with assistance programs, please contact Heidi Holmes-Nagy at hholmesnagy@co.slo.ca.us or 805-781-5500.

Resources:

- [Resource Guide for Pharmacies to Prevent Delayed COVID-19 Treatment](#) (CDPH)
- [Sunsetting the U.S. Government COVID-19 Therapeutics Distribution Program](#) (ASPR)
- [Introduction of Prescription Oral Antivirals for COVID-19 to the Commercial Market](#) (CMS)

PAXCESS™

Patient Support Program

For patients prescribed PAXLOVID™ (nirmatrelvir tablets; ritonavir tablets), the PAXCESS™ Patient Support Program offers the following:

- Insurance benefits verification
- Ability to enroll online
- Live PAXCESS representatives who can provide information about insurance benefits and program eligibility
- Help with identifying financial assistance resources, including:

Co-Pay Savings Program*



for eligible, commercially insured patients

US Government Patient Assistance Program (USG PAP)†



operated by Pfizer for Medicare and Medicaid, and uninsured patients beginning on December 1, 2023

Need assistance?



CALL TOLL-FREE

1-877-C19-PACK (1-877-219-7225)

Mon-Fri 9AM-9PM ET
Sat-Sun 9AM-5PM ET



VISIT

PAXLOVID.com

Please see Full Prescribing Information, including **BOXED WARNING** and Patient Information, [here](https://PAXLOVID.com) or at PAXLOVID.com.

*Terms and Conditions apply. Please see full terms and conditions at PAXLOVID.com/PAXCESS-terms-and-conditions.

†With a focus on ensuring affordable access for patients, the USG Patient Assistance Program operated by Pfizer will continue to provide patients on Medicare, Medicaid, Tricare, VA Community Care Network, and those who are uninsured access to PAXLOVID for free through December 31, 2024. PAXLOVID, through the USG PAP, is not available to patients who have commercial prescription drug health insurance. The USG PAP operated by Pfizer is an independent program with separate eligibility requirements offered by the United States Department of Health and Human Services and is not owned by Pfizer.



Paxlovid™
(nirmatrelvir 150 mg tablets | ritonavir 100 mg tablets)

A continuación se muestra una traducción del folleto de Pfizer "PAXCESS" traducido el 1 de marzo de 2024, por el Departamento de Salud Pública del Condado de San Luis Obispo:

(En inglés) Below is a translation of Pfizer's flyer, "PAXCESS" translated on March 1, 2024, by the County of San Luis Obispo Public Health Department:

PAXCESS™

Programa de apoyo a pacientes

Para los pacientes que se les ha recetado PAXLOVID™ (nirmatrelvir tablets; ritonavir tablets), el Programa de Apoyo a Pacientes PAXCESS™ ofrece lo siguiente:

- Verificación de los beneficios del seguro
- Posibilidad de inscribirse en línea (www.paxlovid.com/enroll-in-co-pay-program)
- Representantes de PAXCESS en línea que pueden proporcionar más información sobre los beneficios del seguro y la elegibilidad para el programa.
- Ayuda para identificar recursos de asistencia financiera, como

Co-pago
Descuentos
Programa*



para pacientes elegibles con seguro privado

Gobierno de EE.UU.
Descuentos Asistencia
Al Paciente Programa
(USG PAP)†



operado por Pfizer para Medicare y Medicaid, y pacientes sin seguro a partir del 1 de diciembre de 2023

¿Necesita ayuda?

📞 LLAMADA GRATUITA (pida español)
1-877-219-7225

Lunes-Viernes 9am-9pm DE
Sabado-Domingo 9am-5pm DE

👉 VISITA
PAXLOVID.com

Por favor, vea la Información de Prescripción Completa, incluyendo ADVERTENCIA DE CAJA e Información para el Paciente, aquí o en PAXLOVID.com

* Se aplican las condiciones generales. Consulte los términos y condiciones completos en PAXLOVID.com/PAXCESS-terms-and-conditions.

† Con el objetivo de garantizar un acceso asequible a los pacientes, el Programa USG El Programa de Asistencia al Paciente de USG gestionado por Pfizer seguirá proporcionando a los pacientes de Medicare, Medicaid, Tricare, VA Community Care Network y a los que no tienen seguro, acceso gratuito a PAXLOVID hasta el 31 de diciembre de 2024. hasta el 31 de diciembre de 2024. PAXLOVID, a través del USG PAP, no está disponible PAXLOVID, a través del programa PAP del Gobierno de los EE.UU., no está disponible para los pacientes que tienen un seguro médico comercial de medicamentos con receta. El USG PAP gestionado por Pfizer es un programa independiente con requisitos de elegibilidad independientes ofrecido por el Departamento de Salud y Servicios Humanos y no es propiedad de Pfizer.